other material
confidence high
sentiment positive
materiality 0.55
Lixte launches pre-clinical study of LB-100 to target pre-cancerous cells with NKI
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- New pre-clinical study tests if initiated cells with mutant RAS oncogene can be eliminated by LB-100.
- Collaboration with Netherlands Cancer Institute; led by Dr. René Bernards, NKI senior scientist and LIXTE board member.
- Study in animal models expands on LIXTE’s ongoing clinical trials for ovarian and colorectal cancers.
- LB-100 has shown patient tolerance with little toxicity in Phase 1 clinical trials.